Quantcast

GranuFlo Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Dialysis Lawsuits Against Fresenius Medical Care

November 21, 2013

The Firm is evaluating dialysis lawsuits on behalf of individuals who experienced life-threatening cardiac events, including heart attacks, strokes, and sudden cardiac death, allegedly due to GranuFlo and NaturaLyte dialysis concentrates.

New York, New York (PRWEB) November 21, 2013

Hundreds of GranuFlo lawsuit (http://www.thegranuflolawsuit.com/) claims filed in the wake of last year’s recall for GranuFlo and NaturaLyte dialysis concentrates continue to move forward in a federal multidistrict litigation underway in U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. According to court documents dated November 15th, the Court has issued a Protective Order of Confidentiality that governs all hard copy and electronic materials produced by any party in the GranuFlo recall litigation. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“Our Firm hears from alleged victims of GranuFlo and NaturaLyte on a regular basis. We are pleased with the continued progress of the GranuFlo litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices, including numerous individuals in GranuFlo lawsuits. The Firm is offering free and confidential dialysis lawsuit reviews to individuals who may have suffered life-threatening heart events, including heart attacks, strokes and sudden cardiac death, allegedly due to the administration of GranuFlo and NaturaLyte.

GranuFlo Recall

Court documents indicate that at least 393 dialysis lawsuits have been filed in the federal multidistrict litigation since the announcement of the GranuFlo recall last year. All of the claims pending in the proceeding accuse Fresenius Medical Care of failing to provide adequate warnings regarding the use of the two dialysis concentrates, and continuing their aggressive marketing of GranuFlo and NaturaLyte even after those risks became apparent.

In addition to the GranuFlo lawsuit filings pending in the federal multidistrict litigation, court records indicate that scores of additional state claims involving similar allegations have been consolidated in Massachusetts’ Middlesex County Superior Court. (In re Consolidated Fresenius Cases, No. MICV2013-03400-O).

A Class I recall for GranuFlo and NaturaLyte was announced by the U.S. Food & Drug Administration in 2012, at which time the agency warned that use of the products had been linked to metabolic alkalosis, a condition caused by high blood bicarbonate levels which may result in heart attacks, strokes, sudden cardiac death and other catastrophic heart problems in dialysis patients. The announcement of the Class I recall, the FDA’s most serious type of recall, followed the issuance of a March 2012 Urgent Product Notification by Fresenius Medical Care to dialysis clinics nationwide.

In June 2012, The New York Times reported the FDA also launched an investigation into the GranuFlo recall, after it learned that Fresenius Medical Care had notified its own dialysis clinics about the risks associated with GranuFlo and NaturaLyte via an internal memo issued in November 2011. The FDA is trying to determine if the company’s decision not to issue a nationwide warning at that time to all dialysis facilities that used GranuFlo and NaturaLyte violated any federal regulations.*

Alleged victims of GranuFlo or NaturaLyte heart side effects may be entitled to compensation if they suffered a catastrophic cardiac event within 72 hours of administration of one the drugs. To learn more about the GranuFlo recall, please visit Bernstein Liebhard LLP’s website, or visit the Firm’s Facebook page: https://www.facebook.com/granuflolawsuit. For additional information, and to arrange for a free case review, please call 800-511-5092.

*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this

advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info(at)consumerinjurylawyers(dot)com

http://www.thegranuflolawsuit.com/

https://plus.google.com/115936073311125306742?rel=author

For the original version on PRWeb visit: http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb11358779.htm


Source: prweb



comments powered by Disqus